title: Short-term effects of topical tafluprost on retinal blood flow in cats.
abstract: OBJECTIVE
  The aim of this study was to determine the short-term effects of topical tafluprost, a novel prostaglandin F(2) derivative, on feline retinal circulation.
  
  
  METHODS
  Seventeen (17) adult cats were anesthetized with enflurane and mechanically ventilated. One (1) drop of tafluprost (0.0015%; n = 8), latanoprost (0.005%; n = 5), or control vehicle (n = 4) was instilled in 1 eye and the fellow eye was untreated. We measured the intraocular pressure (IOP), vessel diameter, and blood velocity simultaneously for 120 min in the large retinal arterioles and calculated the retinal blood flow (RBF) with a laser Doppler velocimetry system.
  
  
  RESULTS
  Tafluprost 0.0015% significantly increased RBF (maximum change, 42.8 +/- 4.2% [mean +/- standard error of the mean; P < 0.01) and blood velocity (maximum change, 24.1 +/- 3.3%; P < 0.01) for 120 min after instillation; there was no significant change in vessel diameter. Latanoprost 0.005% significantly increased RBF (maximum change, 31.7 +/- 3.4%; P < 0.05); there was no significant change in vessel diameter and blood velocity. There were no significant differences in the IOP reduction among the three groups.
  
  
  CONCLUSIONS
  We observed, for the first time, that topical tafluprost significantly increased RBF in cats, suggesting that dual-action tafluprost may be a beneficial antiglaucomatous agent for reducing IOP and increasing RBF.
authors.affiliation: Department of Ophthalmology, Asahikawa Medical College, Asahikawa, Japan. n_izumi@nifty.com
authors.forename: Naohiro
authors.initials: N
authors.lastname: Izumi
authors.forename: Taiji
authors.initials: T
authors.lastname: Nagaoka
authors.forename: Eiichi
authors.initials: E
authors.lastname: Sato
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Mori
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takahashi
authors.forename: Kenji
authors.initials: K
authors.lastname: Sogawa
authors.forename: Akitoshi
authors.initials: A
authors.lastname: Yoshida
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001783:Blood Flow Velocity / Q000187:drug effects; D002415:Cats; D005260:Female; D007429:Intraocular Pressure / Q000187:drug effects; D017078:Laser-Doppler Flowmetry; D000077338:Latanoprost; D008297:Male; D009883:Ophthalmic Solutions; D011460:Prostaglandins F / Q000008:administration & dosage* / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000494:pharmacology; D012039:Regional Blood Flow / Q000187:drug effects; D012171:Retinal Vessels / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011460:Prostaglandins F; D011461:Prostaglandins F, Synthetic; C485333:tafluprost; D000077338:Latanoprost